ArticleJournal of immunology research2019
Comparative Serological Study for the Prevalence of Anti-MERS Coronavirus Antibodies in High- and Low-Risk Groups in Qatar.
Article in Journal of immunology research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- The incidence of the novel coronavirus SARS-CoV-2 among asymptomatic patients: A systematic review.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020Pooled it
- High Seroprevalence of Anti-SARS-CoV-2 IgM/IgG among Inhabitants of Sakaka City, Aljouf, Saudi Arabia.Vaccines · 2022Article
- Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences.Vaccines · 2022Review
- Unresolved questions in the zoonotic transmission of MERS.Current opinion in virology · 2022Review
- A Review of Coronaviruses Associated With Kawasaki Disease: Possible Implications for Pathogenesis of the Multisystem Inflammatory Syndrome Associated With COVID-19.Clinical medicine insights. Pediatrics · 2022Review
- SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar.Scientific reports · 2021Article
- Current diagnostic approaches to detect two important betacoronaviruses: Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Pathology, research and practice · 2021Review
- Evaluation of Antibody Response in Symptomatic and Asymptomatic COVID-19 Patients and Diagnostic Assessment of New IgM/IgG ELISA Kits.Pathogens (Basel, Switzerland) · 2021Article
- The role of serum specific- SARS-CoV-2 antibody in COVID-19 patients.International immunopharmacology · 2021Review
- Diagnostic Efficiency of Three Fully Automated Serology Assays and Their Correlation with a Novel Surrogate Virus Neutralization Test in Symptomatic and Asymptomatic SARS-COV-2 Individuals.Microorganisms · 2021Article
- Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19.Journal of global health · 2021Article
- Performance evaluation of five ELISA kits for detecting anti-SARS-COV-2 IgG antibodies.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Article
- Summary of the Detection Kits for SARS-CoV-2 Approved by the National Medical Products Administration of China and Their Application for Diagnosis of COVID-19.Virologica Sinica · 2020Review
- The Middle East respiratory syndrome coronavirus in the breath of some infected dromedary camels (Epidemiology and infection · 2020Article
- SARS-CoV-2 antibody characterization in emergency department, hospitalized and convalescent patients by two semi-quantitative immunoassays.Clinica chimica acta; international journal of clinical chemistry · 2020Article
- Preliminary Analysis of B- and T-Cell Responses to SARS-CoV-2.Molecular diagnosis & therapy · 2020Article
- Immune Response to COVID-19: Can We Benefit from the SARS-CoV and MERS-CoV Pandemic Experience?Pathogens (Basel, Switzerland) · 2020Review
- Clinical characteristics of COVID-19 in Saudi Arabia: A national retrospective study.Journal of infection and public health · 2020Article
- Thoughts on What Chemists Can Contribute to Fighting SARS-CoV-2 - A Short Note on Hand Sanitizers, Drug Candidates and Outreach.Angewandte Chemie (International ed. in English) · 2020Article
- From SARS to COVID-19: A previously unknown SARS- related coronavirus (SARS-CoV-2) of pandemic potential infecting humans - Call for a One Health approach.One health (Amsterdam, Netherlands) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infection with Middle East respiratory syndrome coronavirus (MERS-CoV) could be asymptomatic or cause mild influenza-like illness. Therefore, the prevalence of MERS-CoV infections in the general population could be underestimated, which necessitates active surveillance to determine the epidemiological importance of asymptomatic cases. The aim of this study is to evaluate the performance of various serological assays and to estimate the seroprevalence of anti-MERS-CoV antibodies in high- and low-risk groups in Qatar. A total of 4858 samples were screened, including 4719 samples collected from healthy blood donors (BD) over a period of five years (2012-2016), 135 samples from baseline case contacts (CC) collected from individuals in close contact with three positive PCR-confirmed patients (CP), and four samples from MERS-CoV CP. Initial screening using anti-MERS-CoV IgG (IgG rS1-ELISA kit) revealed ten reactive samples from BD (10/4719, 0.21%), one from CC (1/135, 0.74%), and three from CP (3/4, 75%). Samples from CP but not from BD were also reactive by whole-virus anti-MERS-CoV IgG (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.